A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
Not Applicable
Completed
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- Registration Number
- NCT00002292
- Lead Sponsor
- LyphoMed
- Brief Summary
To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pentamidine's efficacy against Pneumocystis carinii in AIDS patients?
How does inhaled pentamidine compare to intravenous administration in treating PCP in HIV-infected individuals?
Are there specific biomarkers that predict response to pentamidine in Pneumocystis pneumonia cases?
What are the adverse event profiles and management strategies for pentamidine in AIDS-related PCP?
What alternative or combination therapies have been explored for Pneumocystis carinii pneumonia in HIV patients?
Trial Locations
- Locations (1)
LyphoMed Inc
🇺🇸Rosemont, Illinois, United States
LyphoMed Inc🇺🇸Rosemont, Illinois, United States